Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study is a Phase 1b, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of multiple-ascending doses of BGB-16673 in adults with chronic spontaneous urticaria (CSU).
Protocol Amendment History 1 change
critical Trial completed 2026-06-19
Trial Details
NCT Number NCT07005713
Lead Sponsor BeiGene
Conditions Chronic Spontaneous Urticaria
Enrollment 34 participants
Start Date 2025-07-19
Primary Completion 2026-04-16 (estimated)
Study Completion 2026-04-16 (estimated)
Updated on ClinicalTrials.gov 2026-06-18